{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T19:15:30Z","timestamp":1768590930525,"version":"3.49.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,12]]},"DOI":"10.7759\/cureus.96659","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T12:46:51Z","timestamp":1762951611000},"source":"Crossref","is-referenced-by-count":1,"title":["Prolonged and Refractory Hypophosphataemia Following Intravenous Ferric Carboxymaltose Administration Delaying Hospital Discharge: A Case Report"],"prefix":"10.7759","author":[{"given":"Zohaib","family":"Sajid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.1923","article-title":"Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women","volume":"28","author":"Wolf M","year":"2013","unstructured":"Wolf M, Koch TA, Bregman DB. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res. 2013, 28:1793-803. 10.1002\/jbmr.1923","journal-title":"J Bone Miner Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-2396","article-title":"FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study","volume":"94","author":"Schouten BJ","year":"2009","unstructured":"Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab. 2009, 94:2332-7. 10.1210\/jc.2008-2396","journal-title":"J Clin Endocrinol Metab"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0167146","article-title":"Choice of high-dose intravenous iron preparation determines hypophosphatemia risk","volume":"11","author":"Schaefer B","year":"2016","unstructured":"Schaefer B, W\u00fcrtinger P, Finkenstedt A, et al.. Choice of high-dose intravenous iron preparation determines hypophosphatemia risk. PLoS One. 2016, 11:e0167146. 10.1371\/journal.pone.0167146","journal-title":"PLoS One"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/ki.2012.176","article-title":"Update on fibroblast growth factor 23 in chronic kidney disease","volume":"82","author":"Wolf M","year":"2012","unstructured":"Wolf M. Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int. 2012, 82:737-47. 10.1038\/ki.2012.176","journal-title":"Kidney Int"},{"key":"ref5","unstructured":"Ferric carboxymaltose (Ferinject). risk of symptomatic hypophosphataemia leading to osteomalacia and fractures. (2020). Accessed: November 12, 2025: https:\/\/www.gov.uk\/drug-safety-update\/ferric-carboxymaltose-ferinject-risk-of-symptomatic-hypophosphataemia-leading-t...."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13189","article-title":"Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions","volume":"83","author":"Bager P","year":"2017","unstructured":"Bager P, Hvas CL, Dahlerup JF. Drug-specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusions. Br J Clin Pharmacol. 2017, 83:1118-25. 10.1111\/bcp.13189","journal-title":"Br J Clin Pharmacol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1097\/MNH.0000000000000329","article-title":"Iron-induced hypophosphatemia: an emerging complication","volume":"26","author":"Zoller H","year":"2017","unstructured":"Zoller H, Schaefer B, Glodny B. Iron-induced hypophosphatemia: an emerging complication. Curr Opin Nephrol Hypertens. 2017, 26:266-75. 10.1097\/MNH.0000000000000329","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2019.22450","article-title":"Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials","volume":"323","author":"Wolf M","year":"2020","unstructured":"Wolf M, Rubin J, Achebe M, et al.. Effects of iron isomaltoside vs ferric carboxymaltose on hypophosphatemia in iron-deficiency anemia: two randomized clinical trials. JAMA. 2020, 323:432-43. 10.1001\/jama.2019.22450","journal-title":"JAMA"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.3319","article-title":"Hypophosphatemia, severe bone pain, gait disturbance, and fatigue fractures after iron substitution in inflammatory bowel disease: a case report","volume":"33","author":"Bartko J","year":"2018","unstructured":"Bartko J, Roschger P, Zandieh S, Brehm A, Zwerina J, Klaushofer K. Hypophosphatemia, severe bone pain, gait disturbance, and fatigue fractures after iron substitution in inflammatory bowel disease: a case report. J Bone Miner Res. 2018, 33:534-9. 10.1002\/jbmr.3319","journal-title":"J Bone Miner Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1258\/acb.2008.008151","article-title":"Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia","volume":"46","author":"Schouten BJ","year":"2009","unstructured":"Schouten BJ, Doogue MP, Soule SG, Hunt PJ. Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia. Ann Clin Biochem. 2009, 46:167-9. 10.1258\/acb.2008.008151","journal-title":"Ann Clin Biochem"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.14643","article-title":"Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside\u2014a systematic review and meta-analysis","volume":"87","author":"Schaefer B","year":"2021","unstructured":"Schaefer B, Tobiasch M, Viveiros A, Tilg H, Kennedy NA, Wolf M, Zoller H. Hypophosphataemia after treatment of iron deficiency with intravenous ferric carboxymaltose or iron isomaltoside\u2014a systematic review and meta-analysis. Br J Clin Pharmacol. 2021, 87:2256-73. 10.1111\/bcp.14643","journal-title":"Br J Clin Pharmacol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01770-2","article-title":"Intravenous iron-induced hypophosphatemia: an emerging syndrome","volume":"38","author":"Glaspy JA","year":"2021","unstructured":"Glaspy JA, Wolf M, Strauss WE. Intravenous iron-induced hypophosphatemia: an emerging syndrome. Adv Ther. 2021, 38:3531-49. 10.1007\/s12325-021-01770-2","journal-title":"Adv Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/426478-prolonged-and-refractory-hypophosphataemia-following-intravenous-ferric-carboxymaltose-administration-delaying-hospital-discharge-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T12:46:53Z","timestamp":1762951613000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/426478-prolonged-and-refractory-hypophosphataemia-following-intravenous-ferric-carboxymaltose-administration-delaying-hospital-discharge-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.96659","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,12]]}}}